Hemostasis Today

May Guo: Inhibiting Anti-PEG Antibody Binding With Randomized PEG
Jun 29, 2026, 20:01

May Guo: Inhibiting Anti-PEG Antibody Binding With Randomized PEG

May Guo, Vice President of Business Development at Biomay AG, Founder and CEO of Novaribo Consulting, shared a post on LinkedIn about a recent article by Philip Dreier et al., published in Chemical Science, adding:

“This study presents the isomerization of PEG to randomized PEG (rPEG) as an efficient approach for inhibiting anti-PEG antibodies (APA) interaction while preserving the advantages of PEG.

rPEGs were obtained via living anionic ring-opening (co)polymerization (AROP) of ethylene oxide (EO) with glycidyl methyl ether (GME).

Chain-end functionalization of rPEGs with lipid anchor groups was conducted to obtain rPEG lipids with C14-chains (ditetradecylacetamide (DTAA), dimyristoyl-glycerol (DMG)).

It is demonstrated that rPEG lipids can prevent APA binding but nevertheless exhibit similar performance in LNPs as comparable PEG lipids.”

Title: Lipids and lipid nanoparticles functionalized with randomized poly(ethylene glycol) (rPEG) for mRNA delivery

Authors: Philip Dreier, Caroline Bockhard, David Seibel, Olaf Soltwedel, Rebecca Matthes, Gregor M Linden, Julian Schmidt, Dominik Göbel, Thomas Endres, Johannes Scheiger, Regine von Klitzing, Emanuel Schneck, Holger Frey

May Guo

Stay updated on all scientific advances with Hemostasis Today.